Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alkaline phosphatase safety and preliminary efficacy in severely burned ICU patients
NL-OMON52814Phase 2Completed
- Sponsor
- Rode Kruis Ziekenhuis
- Start
- Sep 2021
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in burn injury, sponsored by Rode Kruis Ziekenhuis. Primary endpoint: Number of adverse events and serious adverse events within 30 days after AP initiation. Started Sep 2021; status: completed.
02
Conditions
burn injury
Beyond the preview
Go deeper on NL-OMON52814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52814.